Addressing Significant Unmet Medical Needs
Developing next-generation therapeutics for diseases representing significant unmet medical needs and a burden to society, patients and their families.
Discovering and Developing New Therapies
We are a clinical-stage pharmaceutical company focused on discovering and developing novel therapies for central nervous system, respiratory, and metabolic diseases of huge unmet need. We are committed to developing better, safer, and more effective treatments that can have a real impact on the lives of our patients.
Better Patient Outcomes
Better Safety Profiles
Using chemical genomics driven technology, we are leveraging scientific innovations to discover and develop new medicines with better therapeutic options for patients in need.
Delivering Safe and Efficacious Treatment Options
Our lead drug candidate, brilaroxazine (RP5063), is in clinical development for multiple unmet neuropsychiatric indications including schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychotic symptoms in Alzheimer’s disease, Parkinson’s disease psychosis, and attention deficit hyperactivity disorder (ADHD).
Learn more about our completed and ongoing clinical trials.
Latest News
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants
CUPERTINO, Calif., Dec. 16, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Announces Proposed Public Offering
CUPERTINO, Calif., Dec. 16, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia
- Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year - - Generally well-tolerated with low rates of adverse events and discontinuation - - Full data set from open-label extension (OLE) of RECOVER...
Corporate Presentation
